Latest Biotech News

Replimune’s RP-1 (suvolimogene oderparepvec) moved one step closer to a potential FDA decision after an advisory committee vote endorsed the company’s efficacy readouts for unresectable metastatic...

Novo Nordisk took another hit as its Phase 3 cardiovascular outcomes program for ziltivekimab failed to reduce major adverse cardiovascular events versus placebo. The Zeus trial enrolled more than...

Alnylam’s stock tumbled after management trimmed its full-year forecast for ATTR franchise revenues, citing normalization of early launch dynamics. Following disappointing Amvuttra sales and...

Apnimed secured an upsized $192 million IPO to fund launch preparations for Oxnimbi (AD109), its sleep apnea pill aimed at reducing nightly breathing disruptions. The company priced 12 million...

Mimedx agreed to buy Sanara Medtech in a cash-and-stock transaction valuing the deal at approximately $350 million as it looks to move beyond its wound-care business. The company’s wound segment...

Johnson & Johnson entered a new chapter in in vivo CAR T after signing a collaboration with Sail Biomedicines that includes a $785 million upfront payment and an option to acquire the company for...

A death in a China-based, brain-directed gene-editing trial is rekindling questions about oversight for first-in-human personalized therapies. Reporting describes the case of a 6-year-old girl...

Johnson & Johnson and Sail Biomedicines extended momentum in the in vivo CAR T race through a structured collaboration built around Sail’s delivery and expression engineering. The agreement, which...

Investors continue to probe whether AI investment meaningfully changes biotech valuation, according to a new market read on healthcare AI narratives. A review by Fishbone Advisors argues that the...

Guardant Health reported strong growth as oncology testing revenue rose sharply in the second quarter, boosting overall results. Oncology revenue climbed 38% year over year to $219.1 million,...

Johnson & Johnson moved deeper into in vivo CAR T by paying $785 million to partner with Sail Biomedicines, including a $465 million equity investment and milestone payments. The agreement also...

Replimune’s RP1 won support from an FDA advisory committee, with panelists voting 10-3 that the efficacy data are evaluable and clinically meaningful. The recommendation increases the odds the FDA...

Karyopharm’s shares cratered after Xpovio (selinexor) failed again to meet the progression-free survival primary endpoint in a Phase 3 endometrial cancer study. The readout, reported as...

Novo Nordisk’s Phase 3 cardiovascular outcomes trial Zeus failed after its IL-6 inhibitor ziltivekimab did not reduce major adverse cardiovascular events versus placebo. Novo reported an HR of...

Alnylam’s stock dropped sharply after the company lowered sales guidance for Amvuttra and adjusted outlook for its transthyretin amyloidosis franchise. In reporting, Alnylam said Amvuttra’s...

Brenus Pharma secured an €11 million Series A extension (about $12.6 million) and brought in its first APAC investor as international interest grows in its in vivo immunotherapy platform. The...

Tempus AI reported a second-quarter revenue boost driven by strong oncology testing demand, citing continued momentum from FDA approvals. The company raised full-year 2026 revenue guidance to $1.6...

Ratio Therapeutics raised $70 million to advance radiopharmaceutical trial development, funding continued work in its radiopharma pipeline. The Series C was described as coming from existing...

Relation Therapeutics struck a collaboration with GSK to generate large-scale cellular perturbation datasets for use in cellular foundation models. Relation may receive up to $110 million in...

Guardant Health posted a second-quarter revenue gain driven by oncology testing growth, including a sharp rise in colorectal cancer screening volume. The company reported total Q2 revenue of $335...